AZN/GILD/Daiichi: ADC's face stiff hurdles in 1st line lung cancer

AZN GILD ADC

AZN/GILD/Daiichi:

Market expectations are running high for ADC’s toxic payload in NSCLC

We undertake a detailed analysis the current phase late-stage data from AZN/Daiichi’s TROPION and Gilead’s EVOKE program in Lung Cancer and find steep obstacles that may be too high to surmount